Study guide
10.1 Antihypertensives, Heart Failure & Antiarrhythmics
NBME Comprehensive Basic Science Examination CBSE
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Navigation
1.1 Current Exam Facts & Administration 1.2 Content Blueprint & Physician Tasks 1.3 Scoring, Score Reports & Step 1 Readiness
2 Human Development
2.1 Embryology & Congenital Development Patterns 2.2 Normal Age-Related Findings & Well-Patient Care
3 Blood & Hematologic Disease
3.1 Hematopoiesis, RBC Disorders & Anemias 3.2 Hemostasis, Thrombosis & Coagulopathies 3.3 WBC Disorders, Leukemia & Lymphoma Mechanisms
4 Immune System
4.1 Innate & Adaptive Immunity Mechanisms 4.2 Hypersensitivity, Autoimmunity & Immunodeficiency 4.3 Transplant Immunology & Immune Pharmacology
5 Nervous System Anatomy & Disease
5.1 Neuroanatomy Localization & Pathways 5.2 Stroke, Infection, Demyelination & Trauma 5.3 Seizures, Movement Disorders & Neurodegeneration 5.4 Special Senses: Eye & Ear Mechanisms
6 Behavioral Health
6.1 Psychiatric Disorders & Diagnostic Patterns 6.2 Psychopharmacology Mechanisms 6.3 Neurotransmitters, Learning & Behavioral Science
7 Musculoskeletal System
7.1 Bone Physiology, Fracture Healing & Bone Pathology 7.2 Joint Disease, Rheumatology & Connective Tissue 7.3 Muscle, NMJ & Peripheral Nerve Disorders
8 Skin & Soft Tissue
8.1 Dermatopathology High-Yield Lesions 8.2 Inflammation, Wound Healing & Soft-Tissue Infection
9 Cardiovascular Pathophysiology
9.1 Cardiac Cycle, Hemodynamics & Murmurs 9.2 Ischemic Heart Disease & Cardiomyopathy 9.3 Congenital & Valvular Heart Disease 9.4 Vascular Pathology & Hypertension
10 Cardiovascular Pharmacology
10.1 Antihypertensives, Heart Failure & Antiarrhythmics 10.2 Antiplatelets, Anticoagulants & Lipid Drugs
11 Respiratory System
11.1 Pulmonary Mechanics & Gas Exchange 11.2 Obstructive, Restrictive & Vascular Lung Disease 11.3 Pulmonary Infections, Neoplasms & Respiratory Pharmacology
12 Renal Physiology & Electrolytes
12.1 Nephron Transport & Renal Physiology 12.2 Electrolyte Disorders 12.3 Acid-Base Physiology & Compensation
13 Renal Pathology
13.1 Glomerular Disease Mechanisms 13.2 Tubulointerstitial, Vascular & Stone Disease
14 Gastrointestinal System
14.1 GI Physiology, Motility & Digestion 14.2 Esophagus, Stomach & Intestinal Pathology 14.3 Liver, Biliary Tree & Pancreas 14.4 GI Microbiology, Nutrition & Malabsorption
15 Endocrine System
15.1 Hormone Signaling & Hypothalamic-Pituitary Axes 15.2 Thyroid & Parathyroid Disease 15.3 Adrenal Disorders & Steroid Pharmacology 15.4 Diabetes, Glucose Homeostasis & Metabolic Syndrome
16 Reproductive System
16.1 Male & Female Reproductive Physiology 16.2 Pregnancy, Placenta & Developmental Toxicology 16.3 Reproductive Pathology & Hormone-Related Neoplasia
17 Multisystem Processes & Disorders
17.1 Cell Injury, Inflammation & Repair 17.2 Neoplasia Principles & Tumor Biology 17.3 Infection, Sepsis & Multisystem Microbial Disease 17.4 Genetics, Inborn Errors & Environmental Toxicology
18 Biostatistics & Epidemiology
18.1 Study Design, Bias & Causation 18.2 Diagnostic Test Metrics & Screening 18.3 Epidemiology Measures & Population Health
19 Social Sciences & Communication
19.1 Ethics Principles & Decision-Making Capacity 19.2 Communication Skills & Difficult Conversations 19.3 Professionalism, Systems & Practice-Based Learning
20 Integrated Disciplines Capstone
20.1 High-Yield Microbiology Anchors Across Systems 20.2 High-Yield Biochemistry & Molecular Mechanisms 20.3 Integrated Pharmacology Strategy & Exam-Day Execution
10.1 Antihypertensives, Heart Failure & Antiarrhythmics
Key Takeaways Explain This Topic AI
Loop diuretics block NKCC2 in the thick ascending limb; thiazides block NCC in the distal convoluted tubule; K-sparing agents either block ENaC (amiloride, triamterene) or antagonize mineralocorticoid receptors (spironolactone, eplerenone).
ACE inhibitors block angiotensin II formation and raise bradykinin; ARBs block AT1 receptors without bradykinin effects; ARNI combines valsartan with neprilysin inhibition to increase natriuretic peptides.
Dihydropyridine CCBs act mainly on vascular smooth muscle; non-dihydropyridines (verapamil, diltiazem) also depress AV nodal conduction and contractility—avoid combining non-DHPs with beta-blockers when possible.
Heart-failure mortality benefit clusters around ACEI/ARB/ARNI, evidence-based beta-blockers, mineralocorticoid antagonists, and SGLT2 inhibitors via complementary neurohormonal and cardiorenal effects.
Vaughan Williams classes I–IV target Na+ channels, autonomic tone/K+ channels (class II/III overlap conceptually), K+ channels (prolong APD/QT), and Ca2+ channels; amiodarone, digoxin, adenosine, and class Ic agents have high-yield toxicities and use constraints.
Last updated: August 2026
10.1 Antihypertensives, Heart Failure & Antiarrhythmics
Quick Answer: Antihypertensive and HF drugs act on volume (diuretics), RAAS tone (ACEI/ARB/ARNI, aldosterone antagonists), cardiac output/heart rate (beta-blockers, non-DHP CCBs), and vascular resistance (DHP CCBs, hydralazine, nitrates, minoxidil). Antiarrhythmics are organized by Vaughan Williams ion-channel effects; exam stems pair a clinical scenario with a mechanism or toxicity (for example, amiodarone multi-organ effects, digoxin toxicity with hypokalemia, class Ic use after structural heart disease, adenosine AV-node block).
Cardiovascular drugs on the CBSE reward mechanism-first thinking. A stem may show hyperkalemia after starting an ACE inhibitor, cough after lisinopril, bradycardia after verapamil plus a beta-blocker, or QT prolongation after a class III agent. Link each drug class to its molecular target, physiologic effect (preload, afterload, inotropy, chronotropy, dromotropy), and predictable adverse effects.
Diuretics: Classes, Transporters, and Sites
Diuretics reduce extracellular volume and, for some classes, lower peripheral resistance with chronic use. Know the nephron segment and the transporter blocked.
Class Prototype examples Site Molecular target Key electrolyte / clinical notes
Loop Furosemide, bumetanide, torsemide, ethacrynic acid Thick ascending limb NKCC2 (Na-K-2Cl cotransporter) Strong natriuresis; ↓ Mg2+/Ca2+ reabsorption; hypokalemic metabolic alkalosis; ototoxicity risk (esp. ethacrynic acid / high IV rates)
Thiazide / thiazide-like Hydrochlorothiazide, chlorthalidone, metolazone Distal convoluted tubule NCC (Na-Cl cotransporter) Mild–moderate diuresis; hypokalemia, hyponatremia, hypercalcemia (↑ Ca2+ reabsorption), hyperuricemia, hyperglycemia
K-sparing (ENaC) Amiloride, triamterene Cortical collecting duct (principal cells) ENaC Weak diuresis alone; spare K+; hyperkalemia risk
K-sparing (MRA) Spironolactone, eplerenone Collecting duct Mineralocorticoid receptor antagonism Block aldosterone-driven ENaC/Na+/K+-ATPase upregulation; hyperkalemia; spironolactone → gynecomastia (androgen receptor effects)
Loop diuretics inhibit NKCC2, dissipating the medullary osmotic gradient and impairing free-water reabsorption capacity. They remain effective at lower GFRs than thiazides and are first-line for volume overload in decompensated HF. Thiazides are preferred in many primary hypertension regimens when GFR is adequate; they also reduce urinary calcium excretion (useful conceptually in calcium stone formers). Carbonic anhydrase inhibitors (acetazolamide) act mainly in the proximal tubule and are weak diuretics for HTN but high-yield for other uses (altitude, metabolic alkalosis, glaucoma).
Exam pearl: combining a loop or thiazide with an ACEI/ARB and an MRA multiplies hyperkalemia risk and requires electrolyte monitoring—classic polypharmacy traps.
ACE Inhibitors, ARBs, and ARNI
Angiotensin-converting enzyme inhibitors (ACEIs) block conversion of angiotensin I → angiotensin II and reduce degradation of bradykinin. Less angiotensin II means less AT1-mediated vasoconstriction, less aldosterone release, and lower afterload/preload over time. Bradykinin accumulation contributes to dry cough and risk of angioedema . ACEIs also preferentially dilate the efferent arteriole, lowering intraglomerular pressure—renoprotective in diabetic nephropathy but can raise creatinine and cause hyperkalemia, especially in bilateral renal artery stenosis or volume depletion.
ARBs (for example, losartan, valsartan) block AT1 receptors directly. They share many hemodynamic and potassium effects with ACEIs but do not raise bradykinin, so cough/angioedema rates are lower (angioedema is still possible but less frequent). Do not combine ACEI + ARB chronically for routine HTN/HF because dual blockade increases adverse renal and potassium events without proportional outcome gains.
ARNI (sacubitril/valsartan) pairs an ARB with neprilysin inhibition . Neprilysin degrades natriuretic peptides (ANP/BNP) and other vasoactive peptides; inhibiting it increases natriuretic peptide signaling → vasodilation, natriuresis, and favorable remodeling signals. Used in HFrEF with mortality benefit when replacing ACEI/ARB in appropriate patients. Washout from ACEI is required before ARNI to reduce angioedema risk (both pathways can increase bradykinin-related effects).
- Drug class Core mechanism Signature adverse effects
- ACEI ↓ Ang II formation; ↑ bradykinin Cough, angioedema, hyperkalemia, ↑ creatinine, teratogenicity
- ARB AT1 blockade Hyperkalemia, ↑ creatinine, teratogenicity; less cough
- ARNI ARB + neprilysin inhibition Hypotension, hyperkalemia, angioedema risk; ACEI washout needed
- Calcium Channel Blockers: Dihydropyridine vs Non-Dihydropyridine
All clinically used CCBs block L-type voltage-gated calcium channels, but tissue selectivity differs.
Dihydropyridines (DHPs) — amlodipine, nifedipine, felodipine — preferentially relax vascular smooth muscle , lowering systemic vascular resistance (afterload). Reflex tachycardia can occur with short-acting agents. Common effects: peripheral edema (arteriolar dilation → capillary pressure imbalance), flushing, headache. DHPs are useful antihypertensives and antianginals (↓ afterload, coronary vasodilation) but do not meaningfully slow AV nodal conduction at usual doses.
Non-dihydropyridines — verapamil (more cardiac) and diltiazem (intermediate) — reduce heart rate, AV nodal conduction (negative dromotropy), and contractility (negative inotropy) in addition to vasodilation. They treat rate control in atrial fibrillation/flutter and some SVTs, and can help angina by lowering myocardial O2 demand. Avoid in decompensated systolic HF and use caution with beta-blockers (additive bradycardia/AV block). Verapamil is more associated with constipation and stronger negative inotropy than diltiazem.
Beta-Blockers: Selective vs Nonselective
Beta-blockers antagonize catecholamine effects at β-adrenergic receptors.
β1-selective (cardioselective) agents (metoprolol, atenolol, bisoprolol, nebivolol at usual doses) reduce heart rate, contractility, and renin release with relatively less β2 blockade.
Nonselective agents (propranolol, nadolol, carvedilol also has α1 blockade) block β1 and β2; β2 blockade can worsen bronchospasm and mask hypoglycemia recovery signals.
Combined α1/β blockers (carvedilol, labetalol) add vasodilation via α1 antagonism—useful in HF (carvedilol) or hypertensive urgency/pregnancy contexts (labetalol conceptually).
ISA (intrinsic sympathomimetic activity) agents are less emphasized clinically for outcome-driven HF care.
Evidence-based HF beta-blockers classically include carvedilol, metoprolol succinate, and bisoprolol . Mechanisms of benefit: reduced myocardial O2 demand, improved diastolic filling time, blunted arrhythmogenic catecholamine effects, and reverse remodeling over time—not acute inotropy.
Adverse effects high-yield for exams: bradycardia, AV block, fatigue, erectile dysfunction, dyslipidemia/glucose effects with some agents, exacerbation of decompensated HF if started aggressively, and nonselective agents in reactive airway disease.
Alpha-Blockers and Direct Vasodilators
α1-antagonists (prazosin, doxazosin, terazosin) reduce arteriolar and venous tone → lower BP; useful also for BPH symptoms. First-dose orthostatic hypotension is classic. They are not first-line monotherapy for primary HTN in modern outcome-driven algorithms but remain mechanistically testable.
Hydralazine is a direct arterial vasodilator (reduces afterload). Compensatory sympathetic activation and fluid retention often require co-therapy with a beta-blocker and diuretic. Associated with drug-induced lupus-like syndrome (hydralazine, procainamide classic pair). Nitrates (nitroglycerin, isosorbide dinitrate) primarily increase NO → cGMP → venous capacitance (↓ preload) with arterial effects at higher doses; combine with hydralazine in selected HF regimens (for example, self-identified Black patients with HFrEF historically studied). Minoxidil opens K+ channels in vascular smooth muscle → hyperpolarization and arterial dilation; potent afterload reduction with marked reflex tachycardia and fluid retention; hypertrichosis is a signature side effect.
Heart Failure: Neurohormonal Targets
Chronic HFrEF is driven by maladaptive activation of the sympathetic nervous system and RAAS, plus other pathways. Disease-modifying pillars target these axes:
ACEI / ARB / ARNI — reduce afterload and aldosterone-driven remodeling.
Beta-blockers (evidence-based) — blunt catecholamine toxicity and lower heart rate.
Mineralocorticoid receptor antagonists — block residual aldosterone effects (fibrosis, Na+ retention, K+ loss).
SGLT2 inhibitors (for example, dapagliflozin, empagliflozin) — originally antihyperglycemics; reduce HF hospitalization/mortality via natriuresis/osmotic diuresis, hemodynamic and metabolic effects, and cardiorenal protection even in many patients without diabetes. For basic-science exams, remember SGLT2 blockade in the proximal tubule increases urinary glucose and Na+ excretion and has become a high-yield HF concept beyond pure glucose control.
Acute decompensated HF still uses loop diuretics for congestion; inotropes and vasodilators appear in selected shock/afterload scenarios but are not chronic mortality pillars. Digoxin may help symptoms/rate control in selected patients without reducing overall mortality the way the neurohormonal quartet does.
Antiarrhythmics: Vaughan Williams I–IV
Organize by dominant ion-channel / autonomic effect:
Class Primary action Electrophysiologic effect Prototypes / notes
Ia Moderate Na+ block + some K+ block ↑ QRS, ↑ QT Quinidine, procainamide, disopyramide; procainamide → drug-induced lupus; quinidine → cinchonism
Ib Fast Na+ block (preferentially ischemic tissue) Little effect on QRS in normal tissue; shortens APD somewhat Lidocaine, mexiletine; CNS toxicity (lidocaine)
Ic Strong Na+ block Marked ↑ QRS; use-dependent Flecainide, propafenone; avoid in structural heart disease / post-MI (CAST-era teaching)
II β-blockade ↓ cAMP; slow SA/AV node Metoprolol, etc.; rate control, suppress catecholamine-triggered arrhythmias
III K+ channel block (IKr and others) Prolong APD and QT → risk of torsades Amiodarone, sotalol, dofetilide, ibutilide; sotalol also has β-blockade
IV Non-DHP CCB Slow AV node (Ca2+-dependent tissue) Verapamil, diltiazem
Amiodarone is predominantly class III but multi-channel (Na+, Ca2+, β effects). High-yield toxicities: pulmonary fibrosis, thyroid dysfunction (hyper- or hypo- because iodine-rich structure and peripheral conversion effects), hepatotoxicity, corneal deposits, blue-gray skin, photosensitivity, bradycardia/AV block. Long half-life and extensive tissue distribution.
Digoxin inhibits Na+/K+-ATPase → ↑ intracellular Na+ → reduced Na+/Ca2+ exchange → ↑ intracellular Ca2+ (positive inotropy). Increases vagal tone → slows AV nodal conduction (useful in AF rate control). Toxicity: GI symptoms, visual changes (xanthopsia), arrhythmias including bidirectional VT; hypokalemia potentiates toxicity because digoxin and K+ compete at the pump site.
Adenosine activates A1 receptors on AV nodal cells → opens K+ channels and inhibits Ca2+ currents → transient AV block. Diagnostic/therapeutic for SVT involving the AV node. Extremely short half-life; brief asystole, flushing, chest discomfort expected. Effects antagonized by methylxanthines (theophylline, caffeine); potentiated by dipyridamole.
Class Ic caveat: strong use-dependent Na+ channel blockade can promote reentry and ventricular proarrhythmia in damaged myocardium—classic reason to avoid flecainide/propafenone when coronary disease or reduced EF is present, while they remain options in carefully selected structurally normal hearts (for example, some AF "pill-in-pocket" contexts).
Integration: Mechanism Maps for Exam Stems
When a stem describes a patient with HFrEF, map drugs to remodeling and load reduction rather than "BP pills." When a stem shows hyperkalemia, think ACEI/ARB/ARNI/MRA/ENaC blockers and renal impairment. When a stem shows cough after HTN therapy, prefer ACEI-induced bradykinin over ARB. When bradycardia and constipation appear with rate control, consider verapamil. When multi-organ toxicity appears after long-term arrhythmia therapy, amiodarone leads the differential. When a wide-complex tachycardia treatment discussion involves post-MI patients, class Ic agents are the classic "avoid" answer.
Mastery is the ability to move from clinical vignette → molecular target → expected ECG/lab change → toxicity pattern without memorizing isolated brand lists.